In colon cancer, ARID1A-deficient cells exhibit reduced expression of topoisomerase 2A and a decatenation defect, which render tumor cells sensitive to an ATR serine/threonine kinase inhibitor [92] or PARP inhibitor [93]. The gene discussed is ARID1A; the disease is malignant colon neoplasm.